
|Articles|February 1, 2004
Acne treatment comes of age
Waikoloa, Hawaii - The large, multicenter B.E.S.T. (Balancing Efficacy, Speed and Tolerability) clinical trial provides real-world data, reinforcing the conclusion that tazarotene 0.1 percent cream (Tazorac for acne) applied once daily in the evening is a highly and rapidly effective, well-tolerated treatment for acne vulgaris, said Dina N. Anderson, M.D., at the annual Hawaii Dermatology Seminar in January.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
3
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














